These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 14717024)

  • 1. Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer.
    Bonomi PD
    Am J Health Syst Pharm; 2003 Dec; 60(24 Suppl 9):S16-21. PubMed ID: 14717024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor-targeted therapy with ZD1839: symptom improvement in non-small-cell lung cancer.
    Natale RB
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):39-43. PubMed ID: 15142633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
    Kris MG; Natale RB; Herbst RS; Lynch TJ; Prager D; Belani CP; Schiller JH; Kelly K; Spiridonidis H; Sandler A; Albain KS; Cella D; Wolf MK; Averbuch SD; Ochs JJ; Kay AC
    JAMA; 2003 Oct; 290(16):2149-58. PubMed ID: 14570950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
    Thomas M
    Cancer Nurs; 2003 Dec; 26(6 Suppl):21S-25S. PubMed ID: 15025409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy.
    Penne K; Bohlin C; Schneider S; Allen D
    Cancer Nurs; 2005; 28(6):481-6. PubMed ID: 16330971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZD1839 (Iressa): what's in it for the patient?
    Natale RB; Zaretsky SL
    Oncologist; 2002; 7 Suppl 4():25-30. PubMed ID: 12202785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacy practice issues with targeted therapy for lung cancer.
    Jones S
    Am J Health Syst Pharm; 2003 Dec; 60(24 Suppl 9):S11-5. PubMed ID: 14717023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.
    Natale RB
    Clin Lung Cancer; 2003 Sep; 5 Suppl 1():S11-7. PubMed ID: 14641989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).
    Pao W; Miller VA; Kris MG
    Semin Cancer Biol; 2004 Feb; 14(1):33-40. PubMed ID: 14757534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
    Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
    [No Abstract]   [Full Text] [Related]  

  • 11. ZD1839 (Iressa) in non-small cell lung cancer.
    Herbst RS; Kies MS
    Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
    Vansteenkiste J
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):5-17. PubMed ID: 14748652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current management of advanced non-small cell lung cancer: targeted therapy.
    Isobe T; Herbst RS; Onn A
    Semin Oncol; 2005 Jun; 32(3):315-28. PubMed ID: 15988686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale.
    Cella D
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):39-48. PubMed ID: 12644983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer.
    Glover KY; Perez-Soler R; Papadimitradopoulou VA
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):83-92. PubMed ID: 14981585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
    Reck M; Gatzemeier U
    Respir Med; 2005 Mar; 99(3):298-307. PubMed ID: 15733505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.